SAN DIEGO -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today the first patient has been dosed in a closed loop control ("artificial pancreas") clinical study involving Halozyme's ...
The MarketWatch News Department was not involved in the creation of this content. Dr. Alexander Rivkin, a global pioneer in Non-Surgical Rhinoplasty, contributes to an award winning international ...
SAN DIEGO, Dec. 21, 2012 /PRNewswire via COMTEX/ -- Halozyme Therapeutics, Inc. HALO -2.65% announced today that it has entered into a worldwide Collaboration and License Agreement with Pfizer Inc.
Lower concentrations of hyaluronidase were as effective as higher concentrations at degrading hyaluronic acid fillers, according to study results published in Dermatologic Surgery. Margit L. W. Juhász ...
Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use additive products, like its hyaluronidase. Under the Inflation Reduction Act, the ...
The COVID-19 pandemic had a significant impact on the hyaluronidase market. For instance, a 2021 article by the British Association of Aesthetic Plastic Surgeons (BAAPS) stated that there was a 27% ...
Further commercializing its Enhanze drug delivery technology, Halozyme Therapeutics has partnered with Janssen Biotech to develop new products. Halozyme will get $15 million to start, and is eligible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback